Literature DB >> 31125255

Analysis of Cre-mediated genetic deletion of Gdf11 in cardiomyocytes of young mice.

Jessica Garbern1,2, Amy C Kristl1, Vinicius Bassaneze1,3, Ana Vujic1, Henk Schoemaker3, Rebecca Sereda1, Liming Peng4, Elisabeth M Ricci-Blair1, Jill M Goldstein1, Ryan G Walker1, Shalender Bhasin4, Amy J Wagers1,5,6, Richard T Lee1,3.   

Abstract

Administration of active growth differentiation factor 11 (GDF11) to aged mice can reduce cardiac hypertrophy, and low serum levels of GDF11 measured together with the related protein, myostatin (also known as GDF8), predict future morbidity and mortality in coronary heart patients. Using mice with a loxP-flanked ("floxed") allele of Gdf11 and Myh6-driven expression of Cre recombinase to delete Gdf11 in cardiomyocytes, we tested the hypothesis that cardiac-specific Gdf11 deficiency might lead to cardiac hypertrophy in young adulthood. We observed that targeted deletion of Gdf11 in cardiomyocytes does not cause cardiac hypertrophy but rather leads to left ventricular dilation when compared with control mice carrying only the Myh6-cre or Gdf11-floxed alleles, suggesting a possible etiology for dilated cardiomyopathy. However, the mechanism underlying this finding remains unclear because of multiple confounding effects associated with the selected model. First, whole heart Gdf11 expression did not decrease in Myh6-cre; Gdf11-floxed mice, possibly because of upregulation of Gdf11 in noncardiomyocytes in the heart. Second, we observed Cre-associated toxicity, with lower body weights and increased global fibrosis, in Cre-only control male mice compared with flox-only controls, making it challenging to infer which changes in Myh6-cre;Gdf11-floxed mice were the result of Cre toxicity versus deletion of Gdf11. Third, we observed differential expression of cre mRNA in Cre-only controls compared with the cardiomyocyte-specific knockout mice, also making comparison between these two groups difficult. Thus, targeted Gdf11 deletion in cardiomyocytes may lead to left ventricular dilation without hypertrophy, but alternative animal models are necessary to understand the mechanism for these findings. NEW & NOTEWORTHY We observed that targeted deletion of growth differentiation factor 11 in cardiomyocytes does not cause cardiac hypertrophy but rather leads to left ventricular dilation compared with control mice carrying only the Myh6-cre or growth differentiation factor 11-floxed alleles. However, the mechanism underlying this finding remains unclear because of multiple confounding effects associated with the selected mouse model.

Entities:  

Keywords:  Myh6-cre; cardiomyocytes; cardiomyopathy; growth differentiation factor 11; myostatin

Mesh:

Substances:

Year:  2019        PMID: 31125255      PMCID: PMC6692736          DOI: 10.1152/ajpheart.00615.2018

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  26 in total

1.  A modification of the masson trichrome technique for routine laboratory purposes.

Authors:  J Goldner
Journal:  Am J Pathol       Date:  1938-03       Impact factor: 4.307

2.  Transvection effects involving DNA methylation during meiosis in the mouse.

Authors:  Minoo Rassoulzadegan; Marc Magliano; François Cuzin
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

3.  The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism.

Authors:  Melissa F Jackson; Dung Luong; Dor Dor Vang; Dilip K Garikipati; James B Stanton; O Lynne Nelson; Buel D Rodgers
Journal:  J Endocrinol       Date:  2012-03-19       Impact factor: 4.286

4.  Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11.

Authors:  A C McPherron; A M Lawler; S J Lee
Journal:  Nat Genet       Date:  1999-07       Impact factor: 38.330

5.  Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial.

Authors:  Bo Nordenskjöld; Johan Rosell; Lars-Erik Rutqvist; Per-Olof Malmström; Jonas Bergh; Nils-Olof Bengtsson; Thomas Hatschek; Arne Wallgren; John Carstensen
Journal:  J Natl Cancer Inst       Date:  2005-11-02       Impact factor: 13.506

6.  Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin.

Authors:  Suzanne Reisz-Porszasz; Shalender Bhasin; Jorge N Artaza; Ruoqing Shen; Indrani Sinha-Hikim; Aimee Hogue; Thomas J Fielder; Nestor F Gonzalez-Cadavid
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-06-24       Impact factor: 4.310

7.  Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy.

Authors:  Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

8.  Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse.

Authors:  Indroneal Banerjee; John W Fuseler; Robert L Price; Thomas K Borg; Troy A Baudino
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-06-29       Impact factor: 4.733

9.  Redundancy of myostatin and growth/differentiation factor 11 function.

Authors:  Alexandra C McPherron; Thanh V Huynh; Se-Jin Lee
Journal:  BMC Dev Biol       Date:  2009-03-19       Impact factor: 1.978

10.  Variable expression of Cre recombinase transgenes precludes reliable prediction of tissue-specific gene disruption by tail-biopsy genotyping.

Authors:  Tim J Schulz; Markus Glaubitz; Doreen Kuhlow; René Thierbach; Marc Birringer; Pablo Steinberg; Andreas F H Pfeiffer; Michael Ristow
Journal:  PLoS One       Date:  2007-10-10       Impact factor: 3.240

View more
  9 in total

1.  Steady-state and regenerative hematopoiesis occurs normally in mice in the absence of GDF11.

Authors:  Jill M Goldstein; Hilal Sengul; Kathleen A Messemer; Marcos Fernández-Alfara; Jessica C Garbern; Amy C Kristl; Richard T Lee; Amy J Wagers
Journal:  Blood       Date:  2019-11-14       Impact factor: 22.113

2.  Variation in zygotic CRISPR/Cas9 gene editing outcomes generates novel reporter and deletion alleles at the Gdf11 locus.

Authors:  Jill M Goldstein; Austin Valido; Jordan P Lewandowski; Ryan G Walker; Melanie J Mills; Kathleen A Messemer; Paul Besseling; Kyu Ha Lee; Samuel J Wattrus; Miook Cho; Richard T Lee; Amy J Wagers
Journal:  Sci Rep       Date:  2019-12-09       Impact factor: 4.379

Review 3.  Similar sequences but dissimilar biological functions of GDF11 and myostatin.

Authors:  Joonho Suh; Yun-Sil Lee
Journal:  Exp Mol Med       Date:  2020-10-19       Impact factor: 8.718

Review 4.  Role of circulating molecules in age-related cardiovascular and metabolic disorders.

Authors:  Yung Ting Hsiao; Ippei Shimizu; Yohko Yoshida; Tohru Minamino
Journal:  Inflamm Regen       Date:  2022-01-10

5.  Growth differentiation factor 11 accelerates liver senescence through the inhibition of autophagy.

Authors:  Jian Sun; Ying Li; Xiao Yang; Wei Dong; Jiankun Yang; Qi Hu; Cuntai Zhang; Haoshu Fang; Anding Liu
Journal:  Aging Cell       Date:  2021-12-14       Impact factor: 9.304

6.  GDF11 expressed in the adult brain negatively regulates hippocampal neurogenesis.

Authors:  Brittany A Mayweather; Sean M Buchanan; Lee L Rubin
Journal:  Mol Brain       Date:  2021-09-06       Impact factor: 4.041

Review 7.  Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?

Authors:  Jan Frohlich; Manlio Vinciguerra
Journal:  Geroscience       Date:  2020-10-06       Impact factor: 7.713

8.  Growth differentiation factor 11 attenuates cardiac ischemia reperfusion injury via enhancing mitochondrial biogenesis and telomerase activity.

Authors:  Lin Chen; Guangjin Luo; Yameng Liu; Hairuo Lin; Cankun Zheng; Dongxiao Xie; Yingqi Zhu; Lu Chen; Xiaoxia Huang; Donghong Hu; Jiahe Xie; Zhenhuan Chen; Wangjun Liao; Jianping Bin; Qiancheng Wang; Yulin Liao
Journal:  Cell Death Dis       Date:  2021-07-02       Impact factor: 8.469

9.  Heterozygous loss-of-function variants significantly expand the phenotypes associated with loss of GDF11.

Authors:  Thomas A Ravenscroft; Jennifer B Phillips; Elizabeth Fieg; Sameer S Bajikar; Judy Peirce; Jeremy Wegner; Alia A Luna; Eric J Fox; Yi-Lin Yan; Jill A Rosenfeld; Jonathan Zirin; Oguz Kanca; Paul J Benke; Eric S Cameron; Vincent Strehlow; Konrad Platzer; Rami Abou Jamra; Chiara Klöckner; Matthew Osmond; Thomas Licata; Samantha Rojas; David Dyment; Josephine S C Chong; Sharyn Lincoln; Joan M Stoler; John H Postlethwait; Michael F Wangler; Shinya Yamamoto; Joel Krier; Monte Westerfield; Hugo J Bellen
Journal:  Genet Med       Date:  2021-06-10       Impact factor: 8.822

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.